BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually

Speed, Quality, Productivity Drive Research Efforts

Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.

Bristol Myers Squibb Company is revving its R&D engine with the goal of filing 10 new investigational new drug (IND) applications each year for candidates emerging from its various discovery platforms. But the company’s research and development executives insist that the focus on speed and productivity does not mean BMS is compromising on the quality of its therapeutic candidates across oncology, hematology, immunology, cardiovascular diseases and a growing effort in neuroscience.

Key Takeaways
  • BMS is focused on R&D productivity in terms of the number of drugs it develops, speed and the quality of these new medicines across its established and emerging therapeutic areas.

The company described its efforts to boost productivity and bring more drugs forward faster during an R&D day event on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By 

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.

More from Scrip

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.